Novo Nordisk’s SUSTAIN 9 trial was conducted in Asia, Europe and North America. The aim of the trial was to compare the effect of semaglutide s.c. 1.0 mg once-weekly versus placebo as add-on to sodium glucose co-transporter-2 inhibitor (SGLT-2i) monotherapy or in...